These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 3958489

  • 1. Prophylactic treatment of BALB/c mice with cyclosporine A and its analog B-5-49 enhances resistance to Leishmania major.
    Behforouz NC, Wenger CD, Mathison BA.
    J Immunol; 1986 Apr 15; 136(8):3067-75. PubMed ID: 3958489
    [Abstract] [Full Text] [Related]

  • 2. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.
    Belosevic M, Finbloom DS, Van Der Meide PH, Slayter MV, Nacy CA.
    J Immunol; 1989 Jul 01; 143(1):266-74. PubMed ID: 2499629
    [Abstract] [Full Text] [Related]

  • 3. Suppressive effect of cyclosporin A on the development of Leishmania tropica-induced lesions in genetically susceptible BALB/c mice.
    Solbach W, Forberg K, Kammerer E, Bogdan C, Röllinghoff M.
    J Immunol; 1986 Jul 15; 137(2):702-7. PubMed ID: 3487578
    [Abstract] [Full Text] [Related]

  • 4. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection.
    Liew FY, Hale C, Howard JG.
    J Immunol; 1985 Sep 15; 135(3):2095-101. PubMed ID: 4020140
    [Abstract] [Full Text] [Related]

  • 5. Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites.
    Liew FY, Dhaliwal JS.
    J Immunol; 1987 Jun 15; 138(12):4450-6. PubMed ID: 3295049
    [Abstract] [Full Text] [Related]

  • 6. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed-type hypersensitivity.
    Titus RG, Lima GC, Engers HD, Louis JA.
    J Immunol; 1984 Sep 15; 133(3):1594-600. PubMed ID: 6205088
    [Abstract] [Full Text] [Related]

  • 7. The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment.
    Carter KC, Gallagher G, Baillie AJ, Alexander J.
    Eur J Immunol; 1989 Apr 15; 19(4):779-82. PubMed ID: 2786473
    [Abstract] [Full Text] [Related]

  • 8. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK, Mbati PA, Anjili CO, Orago AS, Turco SJ, Githure JI, Koech DK.
    East Afr Med J; 2001 Feb 15; 78(2):90-2. PubMed ID: 11682953
    [Abstract] [Full Text] [Related]

  • 9. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
    Li J, Nolan TJ, Farrell JP.
    Exp Parasitol; 1997 Sep 15; 87(1):47-57. PubMed ID: 9287957
    [Abstract] [Full Text] [Related]

  • 10. Leishmania major: effect of infectious dose on T cell subset development in BALB/c mice.
    Doherty TM, Coffman RL.
    Exp Parasitol; 1996 Nov 15; 84(2):124-35. PubMed ID: 8932762
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cutaneous leishmaniasis in anti-IgM-treated mice: enhanced resistance due to functional depletion of a B cell-dependent T cell involved in the suppressor pathway.
    Sacks DL, Scott PA, Asofsky R, Sher FA.
    J Immunol; 1984 Apr 15; 132(4):2072-7. PubMed ID: 6230400
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterization of effector and specific suppressor T cells.
    Liew FY, Hale C, Howard JG.
    J Immunol; 1982 Apr 15; 128(4):1917-22. PubMed ID: 6120976
    [Abstract] [Full Text] [Related]

  • 17. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S.
    Vaccine; 2004 May 07; 22(15-16):1930-40. PubMed ID: 15121305
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Resistance of mice to experimental leishmaniasis is associated with more rapid appearance of mature macrophages in vitro and in vivo.
    Sunderkötter C, Kunz M, Steinbrink K, Meinardus-Hager G, Goebeler M, Bildau H, Sorg C.
    J Immunol; 1993 Nov 01; 151(9):4891-901. PubMed ID: 8409447
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.